Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...

CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

HEBRON, Conn. (WTNH) — A driver has serious injuries following a rollover crash on Gilead Street in Hebron Monday, state police said. State police said just before 5 p.m. a Ford E350 was driving ...

Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company with a market capitalization of $1.2 billion, announced that Gilead Sciences (NASDAQ:GILD)' option ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers, paving the ...